Jeffry Pirofsky, DO
Physical Medicine & Rehabilitation · Dadeville, ALNPI 1659318004
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations.
Across 76 payments — averaging $23.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$261
- UCB, Inc.$210
- AbbVie$173
- Si-bone, Inc.$114
- Amgen$111
- Jazz Pharmaceuticals Inc.$98
- plus $856 from 20 others
What the payments were for
- Food & beverage$1,824100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 11 | $261 |
| UCB, Inc. | 9 | $210 |
| AbbVie | 7 | $173 |
| Si-bone, Inc. | 1 | $114 |
| Amgen | 5 | $111 |
| Jazz Pharmaceuticals Inc. | 4 | $98 |
| Boston Scientific | 4 | $93 |
| Harmony Biosciences LLC | 2 | $87 |
| AstraZeneca | 4 | $86 |
| Acadia Pharmaceuticals Inc | 4 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $77 |
| Johnson & Johnson(2 entities) | 4 | $72 |
| Abbott | 3 | $56 |
| Genentech USA, Inc. | 2 | $43 |
| Argenx US, Inc. | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Lundbeck LLC | 1 | $22 |
| Eisai Inc. | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
| Orthofix Medical, Inc. | 1 | $20 |
| Immedica Pharma US, Inc. | 1 | $20 |
| Pfizer | 1 | $20 |
| EMD Serono, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iFuse Implant$114
How this compares
$1,824 in reported general payments places this provider in the 75th percentile of 104 physical medicine & rehabilitation providers in Alabama.
See all physical medicine & rehabilitation providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methocarbamol | 114 | $706 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 17 | $376 |
| Methylprednisolone | 12 | $128 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Dadeville
- Don McCormickBirmingham$22K
- Bradly GoodmanBirmingham$15K
- Nelson Santos AgostoBirmingham$14K
- John PantuoscoBirmingham$12K
- Ross LumsdenBirmingham$11K
- Michael RosemoreBessemer$10K
- Stevon BoyettAthens$8K
- David ThomasonDaphne$7K
- Matthew BerkeBirmingham$6K
- Frederick GrahamNorthport$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.